| __timestamp | Neurocrine Biosciences, Inc. | Novo Nordisk A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 17986000 | 26760000000 |
| Thursday, January 1, 2015 | 32480000 | 32169000000 |
| Friday, January 1, 2016 | 68081000 | 32339000000 |
| Sunday, January 1, 2017 | 169906000 | 32124000000 |
| Monday, January 1, 2018 | 248932000 | 33313000000 |
| Tuesday, January 1, 2019 | 354100000 | 35830000000 |
| Wednesday, January 1, 2020 | 433300000 | 36886000000 |
| Friday, January 1, 2021 | 583300000 | 41058000000 |
| Saturday, January 1, 2022 | 752700000 | 50684000000 |
| Sunday, January 1, 2023 | 887600000 | 61598000000 |
| Monday, January 1, 2024 | 1007200000 | 67377000000 |
In pursuit of knowledge
In the competitive landscape of biopharmaceuticals, effective cost management is crucial. Over the past decade, Novo Nordisk A/S and Neurocrine Biosciences, Inc. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Novo Nordisk's SG&A expenses have surged by approximately 130%, reflecting their aggressive expansion and marketing strategies. In contrast, Neurocrine Biosciences has seen a staggering increase of nearly 4,800% in the same period, indicating rapid growth and scaling efforts. By 2023, Novo Nordisk's SG&A expenses reached over 61 billion, dwarfing Neurocrine's 887 million. This disparity highlights the different scales and operational strategies of these companies. As the biopharma industry continues to evolve, understanding these financial dynamics offers valuable insights into corporate strategies and market positioning.
Cost Management Insights: SG&A Expenses for Novo Nordisk A/S and Amgen Inc.
Comparing SG&A Expenses: Novo Nordisk A/S vs Amneal Pharmaceuticals, Inc. Trends and Insights
Novo Nordisk A/S and Vericel Corporation: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Sanofi or Neurocrine Biosciences, Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Neurocrine Biosciences, Inc.
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Catalent, Inc. Trends and Insights
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. and Mesoblast Limited: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Novavax, Inc.